Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

19.39
+0.11000.57%
Volume:1.94M
Turnover:37.76M
Market Cap:2.44B
PE:-10.79
High:19.93
Open:19.67
Low:19.27
Close:19.28
Loading ...

Apellis Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
05 May

High Growth Tech Stocks In The US For May 2025

Simply Wall St.
·
02 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
01 May

Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know

Zacks
·
30 Apr

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

GlobeNewswire
·
30 Apr

Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now?

Insider Monkey
·
30 Apr

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks
·
29 Apr

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Apellis Pharmaceuticals (APLS) and Eton Pharmaceuticals (ETON)

TIPRANKS
·
28 Apr

Apellis Pharmaceuticals Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
22 Apr

BRIEF-Apellis Announces Craig Wheeler To Join The Board Of Directors

Reuters
·
21 Apr

RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating

MT Newswires Live
·
21 Apr

Apellis Announces Craig Wheeler to Join the Board of Directors

THOMSON REUTERS
·
21 Apr

Press Release: Apellis Announces Craig Wheeler to Join the Board of Directors

Dow Jones
·
21 Apr

Apellis Pharmaceuticals Inc : RBC Cuts Target Price to $21 From $24

THOMSON REUTERS
·
21 Apr

BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating

MT Newswires Live
·
17 Apr

BioHarvest Sciences Inc. (BHST) Soars 5.2%: Is Further Upside Left in the Stock?

Zacks
·
15 Apr

RBC Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Keeps Sector Perform Rating

MT Newswires Live
·
03 Apr

Apellis Pharmaceuticals Is Maintained at Sector Perform by Scotiabank

Dow Jones
·
03 Apr

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

Zacks
·
02 Apr

Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases

MT Newswires Live
·
01 Apr